1844064-96-5

Basic information

• Product Name: Velpatasvir Co Povidone
• Synonyms: Velpatasvir Co Povidone
• CAS NO: 1844064-96-5
• Molecular Formula: C39H45N7O5
• Molecular Weight: 691.82
• EINECS: -0
• Mol File: 1844064-96-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 1024.8±65.0 °C(Predicted)
• Appearance: /
• Density: 1.284±0.06 g/cm3(Predicted)
• PKA: 11.22±0.46(Predicted)
• CAS DataBase Reference: Velpatasvir Co Povidone(CAS DataBase Reference)
• NIST Chemistry Reference: Velpatasvir Co Povidone(1844064-96-5)
• EPA Substance Registry System: Velpatasvir Co Povidone(1844064-96-5)

Safety Data

• Hazardous Substances Data: 1844064-96-5(Hazardous Substances Data)

Usage

General Description

Velpatasvir co Povidone is a combination medication that contains velpatasvir, an antiviral medication, and povidone, a polymeric component. Velpatasvir is used in the treatment of chronic hepatitis C virus (HCV) infection, working to inhibit the replication of the virus in the body. It is often used in combination with other antiviral medications to provide a comprehensive treatment approach. Povidone, on the other hand, is a water-soluble polymer that is commonly used as a binder in pharmaceutical products. Together, velpatasvir co povidone works to target and suppress the activity of the hepatitis C virus, helping to improve liver function and overall health in individuals with HCV infection.

Upstream product

• 334769-80-1 (2S,5S)-5-methyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 
• 676560-83-1 (2S,5S)-5-methyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 676560-84-2 (2S,5S)-5-methylpyrrolidine-2-carboxylic acid ethyl ester 
• 896733-29-2 (S)-5-methyl-3,4-dihydro-2H-pyrrole-2-carboxylic acid ethyl ester 
• 913251-58-8 (S)-2-(tert-butoxycarbonylamino)-5-oxohexanoic acid ethyl ester 
• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 
• 1378392-91-6 (2S,5S)-1-tert-butyl 2-(3-chloro-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-9-yl)-5-methylpyrrolidine-1,2-dicarboxylate 
• 1378391-45-7 tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine-1-carboxylate 
• 1378392-97-2 methyl [(2S)-3-methyl-1-{(2S,5S)-2-methyl-5-[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl]pyrrolidin-1-yl}-1-oxobutan-2-yl]carbamate 
• 1378392-94-9 (2S,5S)-tert-butyl 2-(9-chloro-5H-naphtho[c,g]chromeno[8,9-d]imidazol-2-yl)-5-methylpyrrolidine-1-carboxylate 
• 1378392-93-8 (2S,5S)-tert-butyl 2-(9-chloro-4,5-dihydro-5H-naphtho[c,g]chromeno[8,9-d]imidazol-2-yl)-5-(methyl)pyrrolidine-1-carboxylate 
• 1378392-96-1 methyl {(2S)-1-[(2S,5S)-2-(9-chloro-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1378391-86-6 (2S,4S)-tert-butyl 2-(5-iodo-1H-imidazol-2-yl)-4-(methoxymethyl)pyrrolidine-1-carboxylate 
• 1378388-16-9 (2S,4S)-N-(tert-butyloxycarbonyl)-4-(methoxymethyl)-pyrrolidine-2-carboxylic acid 

Downstream Products

• 1377049-84-7 methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 

Relevant articles and documents

Deuterated antiviral active compounds for hepatitis C viruses

The invention relates to antiviral compounds for hepatitis C viruses (HCVs) and nontoxic pharmacologically-acceptable salts thereof, wherein the compounds are represented by a formula I shown in the description and have good bioavailability, and the compounds have potent inhibiting effects on the all-genotypic HCVs. In the structural formula I, R1, R2, R3 and R4 are independently selected from methyl (-CH3) or deuterated methyl (-CD3); X1, X2, X3, X4 and X5 are separately hydrogen (H) or deuterium (D); and one of the R1, the R2, the R3 and the R4 must be deuterated methyl (-CD3) or one of theX1, the X2, the X3, the X4, and the X5 must be deuterium (D).

Preparation of velpatasvir and derivatives thereof

The invention relates to a preparation method of velpatasvir and derivatives thereof. Concretely, the preparation method provided by the invention comprises the step of preparing the velpatasvir and derivatives thereof (definitions of all the groups are described in the specification) by virtue of an intermediate compound shown in a formula. The preparation method provided by the invention has the advantages that byproducts are fewer, cost is low, and the preparation method is applicable to industrial production of velpatasvir. (The formula is described in the specification.).